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ORIGINAL ARTICLE
Gene therapy for long-term restoration of circulating 
thymulin in thymectomized mice and rats
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Thymulin is a thymic peptide possessing hypophysiotropic 
activity and antiinflammatory effects in the brain. We 
constructed a synthetic DNA sequence encoding met-FTS, 
a biologically active analog of thymulin, and subsequently 
cloned it into different expression vectors. A sequence 
optimized for expression of met-FTS in rodents, 5'- 
ATGCAGGCCAAGTCGCAGGGGGGGTCGAACTAGTAG-3', 
was cloned in the mammalian expression vectors 
pCDNA3.1(+) and phMGFP (which expresses the Monster 
Green Fluorescent Protein), thus obtaining pcDNA3.1- 
metFTS and p-metFTS-hMGFP, which express met-FTS 
and the fluorescent fusion protein metFTS-hMGFP, respec­
tively. The synthetic sequence was also used to construct the 
adenoviral vector RAd-metFTS, which expresses met-FTS. 
Transfection of HEK293 and BHK cells with pcDNA3.1- 
metFTS (experimental groups) or pcDNA3.1 (control), led to 
high levels of thymulin bioactivity (> 600 versus <0.1 pg/ml in 
experimental and control supernatants, respectively). Trans­
fection of HEK293 and BHK cells with pmetFTS-hMGFP 
revealed a cytoplasmic and nuclear distribution of the 
fluorescent fusion protein. A single intramuscular (i.m.) 
injection (1O7 plaque forming units (PFU)/mouse or 10s PFU/ 
rat) of RAd-metFTS in thymectomized animals (nondetectable 
serum thymulin) restored serum thymulin levels for at least 
110 and 130 days post-injection in mice and rats, respectively. 
We conclude that RAd-metFTS constitutes a suitable bio­
technological tool for the implementation of thymulin gene 
therapy in animal models of chronic brain inflammation. 
Gene Therapy (2006) 13, 1214-1221. doi:10.1038/ 
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Introduction
Thymulin is a thymic hormone involved in several 
aspects of intra- and extrathymic T-cell differentiation.12 
Thymulin, which is exclusively produced by the thymic 
epithelial cells (TEC), consists of a nonapeptide compo­
nent (termed thymus serum factor or FTS), coupled in an 
equimolecular ratio to the ion zinc,3 which confers 
biological activity to this molecule.4 The metallopeptide 
active form bears a specific molecular conformation that 
has been evidenced by nuclear magnetic resonance.5
There is increasing evidence that, besides its immu­
nomodulatory actions, thymulin possesses hypophysio­
tropic activity.6 More recent studies point to an 
antinflammatory and analgesic activity of thymulin and 
thymulin analogs in the brain, which makes this peptide 
a molecule of clinical interest.7 8
Unfortunately, efforts to clone the gene for thymulin 
have been unrewarding so far. This has prevented the 
assessment of thymulin gene therapy strategies in 
relevant animal models.9 This situation led us to under­
take the design and construction of a synthetic DNA 
sequence encoding a biologically active analog of
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thymulin. We report here, the successful construction 
of such synthetic DNA sequence and the subsequent 
construction of an adenoviral vector which, when 
injected intramuscularly (i.m.) in thymectomized mice 
and rats, induced long-term expression of high circulat­
ing levels of thymulin.
Results
Design of a DNA sequence expressing met-FTS
An open reading frame (ORF) encoding the peptide 
component of FTS was designed by choosing for each 
amino acid, the codon which is most frequently used 
in rat cells.1011 An ATG starting codon and two TAG 
termination codons were added immediately upstream 
and downstream of the FTS coding sequence, respec­
tively (Figure la). When cloned into appropriate mam­
malian expression vectors, the peptide expressed by this 
sequence (here referred to as the met-FTS gene) was 
met-FTS (Figure la). The insertion of two contiguous 
termination codons at the end of the FTS coding 
sequence assured efficient termination of the translation 
process.
Cloning of the met-FTS synthetic gene in pcDNA3.1(+) 
In order to clone the met-FTS gene into the multiple 
cloning site (MCS) of pcDNA3.1(+), a variant (variant #1) 
of the basic sequence, consisting of the met-FTS gene
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Figure 1 DNA constructs encoding met-FTS. A DNA sequence coding for native FTS was designed for optimal expression in rat cells. By 
adding an ATG starting codon upstream and two stop codons downstream this sequence, respectively, it was converted into an ORF for the 
analog met-FTS (a). In turn, this met-FTS ORF was used to generate appropriate synthetic constructs to be cloned in the expression vectors 
pCDNA3.1(+) (b), phMGFP (c), and pD515 (d). For further technical details see the M&M section.
variant • 3
T7 txomoter site
flanked upstream, by a BmiHI and Mini site and 
downstream, by an EcoRV and EcoRI site (Figure lb), 
was prepared by annealing of the corresponding sense 
and antisense DNA strands (see Materials and methods 
(M&M) for technical details). In order to identify the 
more efficient construction method, the same double­
stranded (ds) DNA was prepared by polymerase chain 
reaction (PCR) using the sense DNA strand as template 
and appropriate primers (see M&M section). As ex­
pected, both methods generated identical ds oligonu­
cleotides with the annealing method being simpler 
and the PCR variant having a higher yield. In subsequent 
preparations, only the annealing method was used. 
The dsDNA obtained by annealing was digested 
with Bini/i 11 and EcoRI and ligated into the Binul 11 
and EcoRI sites of the MCS of pcDNA3.1(+), which 
yielded pcDNA3.1-metFTS, a met-FTS expressing vector 
(Figure 2a).
a Bamlll EcoRI
Xmal EcoRV
pcDNA-metFTS
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pmctFTS-hMGFP
C Bam HI Sall
pDC515-(T7)metFTS
Figure 2 Mammalian viral and nonviral expression vectors 
harboring the synthetic gene for met-FTS. pcDNA-metFTS was 
generated by cloning the synthetic met-FTS gene into the BamHI 
and EcoRI sites of the MCS of pcDNA3.1(+) (a). pmetFTS-hMGFP, 
was generated by inserting the met-FTS gene (lacking the two stop 
codons) into the Xr/zul and EcoRV sites of the MCS of phMGFP. This 
insertion left the met-FTS sequence in frame with the gene for 
hMGFP, so that a metFTS-hMGFP could be expressed (b). pDC515- 
metFTS was generated by inserting the T7-metFTS sequence into the 
BamHI and Sall sites of the MCS of the shuttle pDC515 (c).
Biological activity and immunoreactivity of transgenic 
met-FTS
In vitro tests. Baby Hamster Kidney (BHK) and 
Human Embryo Kidney (HEK) 293 cells transfected 
with pcDNA-metFTS, but not those transfected with 
empty pcDNA3.1, showed a high level of expression 
of biologically active and immunoreactive thymulin 
(Figure 3). Although thymulin concentration was much 
lower in the cell supernatants than in the corresponding 
lysates, transgenic thymulin in the supernatants from 
pcDNA-metFTS-transfected cells was much higher than 
the thymulin bioactivity found in the supernatants of rat 
TEC cultures (1.15 + 0.32 pg/ml, ;; = 4), which are the 
natural source of thymulin.
Incubation of the lysates from pcDNA3.1-metFTS- 
transfected HEK293 cells with a polyclonal anti-FTS 
serum completely quenched their thymulin bioactivity 
(Table 1).
In vivo tests. In order to confirm that the thymulin 
bioactivity present in the transfected cells was not an 
in vitro artifact, lysates from HEK293 and BHK cells 
transfected with pcDNA-metFTS, were intraperitoneal 
(i.p.) injected in thymectomized (Tx) mice, which had 
nondetectable preinjection serum thymulin activity. 
Significant levels of biologically active thymulin were 
detected in the serum of the animals 45 min after lysate
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Figure 3 Bioactive and immunoreactive thymulin activity in pcDNA3.1 or pcDNA-met-FTS transfected cells. Thymulin levels were 
measured by bioassay (a and c) and ELISA (b and d) in supernatants and lysates from HEK293 (upper panels) and BHK (lower panels) cells 
transfected with either pcDNA3.1(+) (open columns) or with pcDNA-metFTS (solid columns). Bioactive thymulin concentrations in the 
pcDNA transfected cells are indicated over the corresponding columns (the height of the control columns has been multiplied by 10 in order 
to allow visualization). Error bars represent s.e.m. Double asterisks on columns indicate highly significant differences (P<0.01) from the 
corresponding pcDNA transfected group. .V-value is 3 in all cases.
Table 1 Immunoneutralization of thymulin activity in lysates from
HEK293 cells transfected with pcDNA-metFTS
Antiserum used for incubation Anti-FTS* Anti-KLHb
Thymulin in incubation mix (fg/ml)
Thymulin in postincubation filtrate 
(fg/ml)
2500c
2 + 1 (4)
2500c
2625 ±315 (4)
Abbreviations: FTS, thymus serum factor; KLH, Keyhole Limpet 
Hemocyanin.
Lysates mixed with an equal volume (100 /¡l) of the appropriate 
undiluted antiserum were incubated for 90 min at 37 C. The 
incubation mix was filtered through an Amicon membrane 
(30 kDa cutoff) and bioactive thymulin measured in the filtrates.
*Anti-FTS was raised by immunizing rabbits with synthetic FTS 
coupled to KLH as carrier.
bAnti-KLH, used as an irrelevant antiserum, was raised by 
immunizing rabbits with KHL alone.
cBioactive thymulin concentration was measured in a lysate from 
HEK293 cells transfected with pcDNA-metFTS and an appropriate 
dilution was made so that the final thymulin concentration in the 
incubation mix was 2500 fg/ml.
injection. In contrast, injection of lysates from HEK293 
cells transfected with pcDNA3.1 alone did not induce the 
appearance of detectable thymulin in Tx animals (Figure 
4). Since thymulin is known to restore the sensitivity to 
azathioprine (Az) in spleen cells from Tx or nude mice, 
the splenocytes of Tx mice injected with experimental 
cell lysates were assessed 24 h postinjection. It was found 
that lysate injection restored the splenocyte sensitivity to 
Az in the Tx animals. Injection of control lysates did not 
affect splenocyte sensitivity to Az (Table 2).
Figure 4 Serum thymulin in thymectomized (Tx) mice injected 
with lysates from cells transfected with pcDNA3.1(+) or pcDNA- 
metFTS. Animals received 100-ul i.p. injections of lysates from 
HEK293 and BHK cells transfected with either pcDNA3.1(+) (open 
bars) or pcDNA-metETS (solid bars). The lysates were supplemen­
ted with ZnCl2 (final ZnCl2 concentration, 1.86 /¡m). At 45 min after 
injection, blood was taken and thymulin measured in sera by 
bioassay. Dotted lines represent average serum thymulin levels in 
Tx and intact young (2 months) mice, 6 + 1 and 80 + 16 fg/ml, 
respectively (N = 4). Error bars represent s.e.m. Double asterisks on 
bars indicate highly significant differences (P<0.01) from the 
corresponding pcDNA3.1(+) transfected group. N-value is 4 in all 
cases.
Construction of a mammalian expression vector for a 
metFTS-hMGFP fusion protein
In order to obtain information about the intracellular 
localization of transgenic met-FTS, a second ds oligonu­
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cleotide variant (variant #2) was designed and synthe­
sized. It consisted of the met-FTS gene lacking its STOP 
codons and flanked upstream by a Xmal site and 
downstream by EcoRV and Ncol sites (Figure lc). This 
dsDNA was digested with Xmal and EcoRV and cloned
Table 2 Restoration of splenocyte sensitivity to Az in Tx mice 
injected with lysates from HEK293 cells transfected with pcDNA- 
metFTS
Experimental group Plasmid used for 
transfection
Az sensitivity 
(pg/ml)
Tx mice None 37.1+7.1 (4)
Tx mice pcDNA3.1 33.2 + 8.3 (3)
Tx mice pcDNA-metFTS 2.3 + 0.5 (4)
Intact euthymic mice None 1.0 + 0.3 (3)
Abbreviations: Az, azathioprine; Tx, thymectomized.
Mice were i.p. injected with 100 y<l vehicle or lysate from HEK293 
cells transfected with the indicated plasmid. On the following day 
the animals were killed, splenocytes prepared as indicated for the 
thymulin bioassay (see Materials and methods section) and 
incubated with sheep erythrocytes in the presence of varying 
concentrations of Az. The inhibitory activity of Az on rosette 
formation was determined and expressed as the minimum 
concentation of Az sufficient to inhibit rosette formation. This 
concentration is inversely related to the circulating levels of 
thymulin in the animals. 
into the same sites of the MCS of an expression vector 
harboring the gene for humanized monster green 
fluorescent protein (phMGFP). This procedure yielded 
p(metFTS-hMGFP), a vector expressing a N-fusion of 
met-FTS to hMGFP (Figure 2b).
Transfection of this vector in HEK293 and BHK cells 
revealed a high level of fluorescence, distributed in both 
the nuclear and cytoplasmic compartments (Figure 5).
Construction and testing of an adenoviral vector 
expressing met-FTS
In order to construct an adenoviral vector expressing 
met-FTS, a third ds oligonucleotide variant (variant #3) 
was designed and synthesized. It consisted of the met- 
FTS gene flanked upstream by an EcoRI site and 
downstream by a Sall site. For sequencing purposes the 
phage T7 promoter, preceded by a BamHI site, was 
included upstream the met-FTS sequence (Figure Id). 
The resulting dsDNA construct was digested with 
BamHI and Sall, and cloned into the same sites of the 
MCS of the shuttle pDC515, which yielded pDC515- 
metFTS (Figure 2c). The shuttle plasmid so loaded was 
co-transfected with the Ad5 genomic plasmid 
pBHGfrt(del)El,3FLP, in HEK293 cells, which led to the 
generation of an adenoviral vector, RAd-metFTS, expres­
sing met-FTS under the control of the mouse cytomega­
lovirus (mCMV) promoter.
1217
Figure 5 Intracellular localization of metFTS-hMGFP. Cultures of HEK293 (a and b) and BHK (c and d) cells grown on coverslips were 
transfected with pmetFTS-hMGFP using lipofectamine, according to the manufacturer's protocol. Two days later cells were fixed and 
mounted, (a and c) Phase constrast micrographs, (b and d) Fluorescence images of the corresponding phase images. Arrowheads identify 
cells expressing the transgenic fusion protein. Higher fluorescence intensity in nuclei is probably due to the fact that on the cover slips nuclei 
are thicker than the surrounding cytoplasm. Scale bar = 50 /¡m.
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Supernatants and lysates from HEK293 and BHK cell 
cultures incubated for 3 days with 10s plaque forming 
units (PFU)/ml RAd-metFTS, possessed high levels of 
bioactive thymulin (Table 3). Neither BHK cells nor TEC 
from rat or human origin showed cytopathic effects after 2 
or 4 days incubation with RAd-metFTS (data not shown).
Thymectomized mice and rats (which had nondetect- 
able serum thymulin) respectively, injected i.m. with 107 
and 10“ PFU RAd-metFTS showed high levels of serum 
thymulin for at least 110 and 130 days, respectively 
(maximum expression time tested in both cases). In both 
species, i.m. injection of an adenoviral vector expressing 
/(-galactosidase (RAd-^gal) in Tx animals failed to induce 
detectable serum thymulin levels (Figures 6 and 7). 
Female rats exposed for 100 days to high circulating 
levels of transgenic met-FTS showed body weight and 
patterns of estrous cyclicity comparable to those of their 
RAd-/>gaI-injected counterparts (data not shown).
Discussion
The present study demonstrates the feasibility of 
constructing a synthetic gene for the thymulin analog
Table 3 Thymulin levels in HEK293 and BHK cells transduced 
with RAd-metFTS
Thymulin 
cone, (pg/ml)
Cell type (treatment)
HEK293 
(RAd-FTS)
BHK 
(RAd-FTS)
HEK293 
(RAd-f, gal)
Supernatants
Lysates
267 + 53 (3) 
1066 + 213 (3)
133 + 27 (3)
533 + 107 (3)
0.064 + 0.023 (3)
0.072 + 0.020 (3)
Abbreviations: BHK, baby hamster kidney.
Transduced cells were incubated for two days with the indicated 
vector at a MOI = 2. Thymulin activity was measured by bioassay. 
Data are expressed as mean + s.e.m. (number of wells tested).
met-FTS, which retains the bioactivity of the native 
peptide. This is in line with an early study reporting the 
construction and expression in bacteria of a synthetic 
gene encoding a chimeric protein consisting of FTS fused 
to the C-terminus of Escherichia coli /?-gal. Subsequent 
cleavage of the purified fusion protein with BrCN 
allowed these workers to obtain preparative amounts 
of the peptide.12
Analog studies have demonstrated that the N-terminal 
Glu of FTS is not critical for the biological activity of the 
peptide. Thus, des Glu1 FTS as well as the synthetic 
dodecapeptide Val-Lys-Arg-(N)-FTS have the same 
biological activity as that of FTS.1314 Consequently, at 
the time of gene design, met-FTS was expected to be 
biologically active and therefore was considered to be 
an appropriate thymulin analog to be expressed by our 
prospective synthetic gene.
The in vitro and in vivo experiments reported here, 
show that our synthetic gene is efficiently expressed in 
mammalian cells under the control of both the mouse 
and human CMV promoter. It is worth noting that 
despite the extremely high intracellular levels of trans­
genic thymulin activity achieved in vitro, none of the cell 
lines (except HEK293 cells where the vector is replica­
tive) transduced with RAd-metFTS showed signs of 
cytotoxicity. This is in line with toxicologic studies 
performed in various species and early clinical studies 
documenting that administration of pharmacological 
doses of synthetic thymulin did not have toxic effects 
even in long-term treatments.15
In the mouse thymus, thymulin is immunocytochemi- 
cally detected in small cytoplasmic vacuoles of reticu­
loendothelial cells16,17 and is thought to originate from a 
high molecular weight precursor targeted to the secre­
tory pathway.18 The pancellular localization of the 
transgenic metFTS-hMGFP fusion protein generated 
in this study suggests that met-FTS is initially targeted 
to the cytoplasm but diffuses freely into the nuclear 
compartment.
Figure 6 Time-course of serum thymulin activity in thymecto­
mized (Tx) mice injected with RAd-metFTS. Animals received a 
single i.m. (hindlegs) injection of of 107 PFU in 100 /zl RAd-metFTS 
(open circles) and were bled by exanguination at the indicated post­
injection times. Inset displays an expanded portion of the main plot 
(day 0-21), showing serum thymulin levels in intact mice (dotted 
line) and in Tx mice injected with RAd-/fgal (open squares). Data 
are expressed as mean + s.e.m. (N = 4). A single experiment was 
performed using a total of 60 mice.
Figure 7 Time-course of serum thymulin activity in thymecto­
mized (Tx) rats injected with RAd-metFTS. Animals were thymec­
tomized at Experimental, day —16 (gray circle) and at Experimental, 
day 0 received a single i.m. (hindlegs) injection of 10s PFU in 200 /il 
vehicle, of either RAd-metFTS (solid circles) or RAd-/igal (open 
circles) and were bled from the tail veins at the indicated post­
injection times. Data are expressed as mean + s.e.m. G\' 6). Similar
results were obtained in a second independent experiment (data not 
shown).
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Our in vivo experiments with RAd-metFTS indicate 
that transduced myocytes release met-FTS into the 
bloodstream and can therefore be used as an ectopic 
source of this thymulin analog in gene therapy strategies. 
This is in line with previous studies showing that skeletal 
muscle is a well-suited tissue for efficient viral-vector- 
mediated peptide gene transfer.1920 The prolonged 
in vivo expression of met-FTS in our Tx mice and rats 
(which were fully immunocompetent) is in contrast with 
the usually short-lived transgene expression achieved by 
adenoviral vectors in immunocompetent animals. We 
hypothesize that the long-term expression of RAd- 
metFTS in vivo may be due to the known anti­
inflammatory activity of thymulin, which could prevent 
the immune system of the animals from mounting a 
destructive response against the transduced myocytes. 
This feature of RAd-metFTS makes it a suitable tool for 
the implementation of long-term thymulin gene therapy.
There are a number of potential uses for thymulin as a 
therapeutic agent. Thymulin has been used in the 
treatment of certain autoimmune pathologies.21 Interest­
ingly, recent evidence suggests that thymulin may play a 
role in the brain as an endogenous anti-inflammatory 
factor.7 8 Since thymulin traverses the brain-blood barrier 
and has no toxic effects even in high doses, i.m. injection 
of RAd-metFTS could generate sustained, pharmacolo­
gically effective levels of serum and brain thymulin for 
the amelioration of pathologies involving chronic brain 
inflammation.
We conclude that the construction of an adenoviral 
vector able to induce sustained high circulating levels 
of a biologically active thymulin analog represents a 
significant initial step in the exploration of the therapeu­
tic potential of this molecule.
Materials and methods
Animals and in vivo procedures
Young (4—9 week) C57BL/6 male and female mice as well 
as young (8-10 week) Sprague-Dawley female rats were 
raised in our animal facilities (INIBIOLP). Animals had 
free access to food and water and were kept at 22 °C with 
a light/dark cycle of 12/12 h. All experiments on 
animals were performed in conformity with the Guide­
lines on Handling and Training of Laboratory Animals, 
published by the Universities Federation for Animal 
Welfare.22
Thymectomy was performed by aspiration with the 
animals under Avertin (2,2,2 tribromoethanol) anesthesia 
(0.4mg/g BW, i.p.). Thymectomized animals were used 
at least 10 days after surgery in order to ensure absence 
of circulating thymulin.
Cell cultures
HEK293, BHK cell lines as well as the rat thymic 
epithelial cell (TEC) line IT-76M1 were used. The TEC 
IT-76M1 cells were originally produced by Kasahara and 
Itoh,23 who described their morphologic and functional 
characteristics. Cell lines were grown in Eagle's mini­
mum essential medium (MEM), 16.8 mM HEPES buffer 
(pH 7.0), 2 mM glutamine, 0.1 mM nonessential amino 
acids, 20 mg/1 penicillin/streptomycin, 3.3 mg/1 ampho­
tericin B, 2.2 g/1 NaHCO3 and 10% (v/v) fetal bovine 
serum. They were grown at 37°C in a humidified 
atmosphere of 95% air-5% CO2. Cells were fed every 
3-4 days and split when confluent.
Mammalian expression vectors
The pcDNA3.1(+) eukaryotic expression vector (Invitro- 
gen Corp., Carlsbad, CA, USA) was used to clone and 
express the first version (Variant #1) of our FTS-encoding 
DNA construct. This vector uses the human cytomega­
lovirus (CMV) immediate early promoter to drive the 
cloned gene, with the bovine growth hormone poly­
adenylation signal located downstream the polylinker.
The humanized Monster Green™ Fluorescent Protein 
(phMGFP) mammalian expression vector (Promega 
Corp., Madison, WI, USA) was used to fuse our thymulin 
analog to the N-terminus of hMGFP in order to monitor 
the intracellular targeting of the analog. The hMGFP 
synthetic gene is driven by the hCMV promoter, with the 
late SV40 polyadenylation signal located downstream 
the gene.
Preparation of double-stranded oligonucleotides 
coding for met-FTS
Each of the three FTS-encoding ds deoxyoligonucleotide 
variants used in this study (see Results) was prepared 
employing the corresponding sense and antisense 
synthetic single-stranded (ss) oligonucleotides which 
were purchased from Invitrogen as reverse phase 
chromatography-purified (cartridge) preparations. Each 
of the dsDNA variants was prepared by mixing 1 nmol of 
each of the appropriate sense and antisense met-FTS 
oligonucleotides in 50 fit annealing buffer (10 mM Tris- 
HC1, pH 7.5, 100 mM NaCl, 1 mM EDTA). The mix was 
placed in a thermocycler (Hybaid, model PCR Express, 
UK) and submitted to a two-step heating sequence (95 °C 
for 10 min followed by 89°C for 15 min). The heating 
process was followed by a programmed stepwise cooling 
sequence consisting of a decrease in l°C/min until 4°C. 
The resulting synthetic dsDNA oligonucleotides were 
cut with appropriate restriction endonucleases and 
purified by native 20% polyacrylamide gel electrophor­
esis (PAGE) in 1 x TBE buffer. Once the DNA constructs 
were cloned in the indicated expression vectors, they 
were sequenced in order to confirm that they were in 
frame and without error. Cloning was performed by 
standard procedures,24 using for transformation the 
E. coli K-12 strain JM109 (Promega) which was grown 
aerobically in Luria-Bertani (LB) medium at 37°C. In 
some cases ds oligonucleotides coding for FTS were 
prepared by PCR, using the following primers (Invitro­
gen): 5'-GGATCCACGCGTATGCAGG-3' (sense) and 
5'-CCGGAATTCGATATCCTACTAGTTCG-3' (antisense), 
and standard PCR protocols.24 Briefly, the appropriate 
sense FTS ss oligonucleotide was mixed with the primers 
and submitted to 30 thermal cycles consisting of 30 s at 
95°C, 30 s at 53°C and 1 min at 72°C, for each cycle. 
Finally the mix was left 5 min at 72°C and then cooled at 
4°C. The resulting dsDNA oligonucleotides were cut 
with appropriate restriction endonucleases and purified 
by PAGE as indicated above.
Adenoviral vector construction
A recombinant adenoviral (RAd) vector harboring the 
met-FTS synthetic gene was constructed by a variant of 
the two plasmid method25 employing the AdMax®
1219
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plasmid kit (Microbix, Canada). This kit uses a shuttle 
plasmid (pDC515) containing a MCS and a FRT recogni­
tion site for the yeast FLP recombinase. This cassette is 
flanked by sequences of the adenovirus type 5 (Ad5) El 
region. The second plasmid of the kit, the genomic 
plasmid pBHGfrt(del)El,3 FLP, consists of the entire 
genome of Ad5, containing deletions in the regions El 
and E3. Upstream the El deletion, pBHGfrt(del)El,3FLP 
contains an expression cassette for the gene of yeast FLP 
recombinase and immediately downstream the El dele­
tion, a FRT recognition site has been inserted. Once the 
thymulin synthetic gene was inserted into the shuttle, 
both plasmids were co-transfected into HEK293 cells. 
In co-transfected HEK293 cells, FLP recombinase is 
expressed and efficiently catalyzes the site-directed 
recombination of the expression cassette of pDC515- 
metFTS into the left end of pBHGfrt(del)El,3FLP, thus 
generating the genome of the desired recombinant 
adenoviral vector, RAd-metFTS. The newly generated 
RAd was rescued from HEK293 cell lysates and plaque 
purified. It was further purified by ultracentrifugation in 
CsCl gradient. Final virus stocks were titrated by a serial 
dilution plaque assay.
Recombinant adenoviral vector expressing 
^-galactosidase
This RAd was kindly provided by Dr Michel Perricau- 
det, Institut Gustave Roussy, Villejuif, France. In this 
vector, the El genomic region has been replaced by an 
expression cassette containing the E. coli lacZ reporter 
gene under the control of the Rous sarcoma virus long- 
terminal repeat (RSV-LTR). The vector was expanded in 
HEK293 cells and purified and titrated as indicated for 
RAd-metFTS.
Thymulin bioassay
Biologically active thymulin was measured in cell 
cultures and serum by a rosette bioassay described in 
detail elsewhere.26 This method is based on the ability of 
thymulin to restore the inhibitory effect of Az on rosette 
formation in spleen cells from Tx mice. Briefly, sera, cell 
lysates or supernatants were filtered through membranes 
(30 kDa cutoff; YMT micropartition system, PMS-I 
Amicon Corporation, Denver, CO, USA) and the ultra­
filtrates were diluted serially and incubated for 90 min at 
37°C with spleen cells from C57BL/6 Tx mice in the 
presence of 10 jzg Az/ml, a concentration that inhibits 
rosette formation in normal but not Tx mice. Rosettes 
were then allowed to form by centrifugation with sheep 
red blood cells and counted in a hemacytometer after 
gentle resuspension. In the presence of thymulin, rosette 
formation was inhibited by Az. The inhibitory activity 
of samples was compared with that of a standard 
curve using synthetic thymulin (a kind gift of Dr Peter 
Heinklein, Humboldt University, Berlin). Values were 
expressed as bioactive thymulin concentration in the 
sample. The sensitivity of the assay is lx 10 n g 
thymulin/ ml.
Thymulin ELISA
Immunoreactive thymulin (i.e., FTS and FTS-Zn) was 
determined by a previously described ELISA with some 
modifications.27 Briefly, in low-binding microtiter plates 
60 sample or synthetic FTS standard were mixed 
with 60 [A rabbit anti-FTS (prepared by JMP; final 
dilution 1/2000) and incubated overnigth at 4°C. The 
mix was transferred to high-binding microtiter plates 
coated with 100 ng synthetic FTS per well. After 1 h 
incubation at 37°C, plates were washed three times with 
PBS containing 0.1% triton X-100. The amount of anti- 
FTS bound to the solid phase was determined color- 
imetricaly using the Universal ABC elite® kit (Vector 
Laboratories Inc., Burlingame, CA, USA), employing the 
ABTS peroxidase substrate for color development. The 
sensitivity of the assay is 2 x 10 [0 g FTS/ml.
Statistical analysis
Data were expressed as mean + s.e.m., unless otherwise 
indicated. Statistical comparisons between experimental 
groups were performed by ANOVA followed by 
Duncan's multiple range test when appropriate.
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